wire - news in brief

« BACK

Health



Results 1 - 50 of 1999.
1 2 3 4 5 ... 40 Next »


Pharmacology - Health - 08:00
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (I T) formulation in older patients with SMA to further support registration Basel, Septembe

Health - 22.09.2020
Most people infected with SARS-CoV-2 develop symptoms
While some people who contract SARS-CoV-2 infections never experience any symptoms, there remains disagreement about what proportion of total infections these cases comprise.

Health - Pharmacology - 21.09.2020
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score - confirming substantial benefit for premenopausal women with HR+/HER2- advanced bre

Health - Pharmacology - 18.09.2020
Patches to detect when a viral disease is about to get worse
Xsensio, an EPFL spin-off, has just been awarded CHF 1.8 million in EU funding to adapt its Lab-on-Skin(TM) sensing patches so that they can detect when a viral illness like the flu or COVID-19 is about to get worse.

Health - Pharmacology - 16.09.2020
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
HIV continues to be a major global health issue, having claimed almost 33 million lives.

Pharmacology - Health - 16.09.2020
Novartis Tafinlar + Mekinist demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1   Adjuvant treatment with

Life Sciences - Health - 15.09.2020
Catalyst Fund selects six projects in its 2020 funding round
The Catalyst Fund - supported by the Bertarelli Foundation - has selected six research projects to fund this year. Led by professors from EPFL and other Swiss Universities, these projects all aim to develop new treatment options for neurological disorders. Created by the Bertarelli Foundation in 2017, the Catalyst Fund aims to invest in translational projects targeting innovative approaches for diseases affecting the brain, spinal cord, peripheral nervous system and sensory organs.

Computer Science - Health - 15.09.2020

Social Sciences - Health - 15.09.2020
Older adults prefer to remain in their home
Older adults prefer to remain in their home
Living at home in old age: This is what most older adults want. As a result, there is a high demand for senior apartments and tailor-made services for the care of older adults in need of assistance in their own households.

Computer Science - Health - 15.09.2020
The
The "black box" problem
A bioethicist and a neuroinformatics scientist discuss how machines are becoming more intelligent and why the advances in technology are leading to new ethical challenges.

Campus - Health - 14.09.2020

Pharmacology - Health - 14.09.2020
European Medicines Agency (EMA) approves safety label update for Novartis Beovu
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD     The update includes the additional characterization of retinal vasculitis a

Health - Computer Science - 14.09.2020
Putting the users centre stage
Even if we succeed in combatting the COVID crisis, the challenges for the health system will not simply disappear. Digital technologies can be developed to help meet ongoing challenges; Nicole Wenderoth explains what should be borne in mind here. Across the globe, the COVID-19 pandemic has pushed healthcare systems to their limits, at least for the moment.

Pharmacology - Health - 11.09.2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naļve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naļve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di

Health - Administration - 11.09.2020
Coronavirus: No quarantine for persons entering from border regions
At its meeting on 11 September, the Federal Council decided on the quarantine rules for persons entering Switzerland from neighbouring countries: only those regions of neighbouring countries where th

Health - Administration - 10.09.2020

Health - Life Sciences - 08.09.2020
LifeTime - Researchers partner to improve European healthcare
LifeTime - Researchers partner to improve European healthcare
The FMI is a partner of the pan-European LifeTime initiative. In two publications, researchers involved with the initiative - including FMI group leader Susan Gasser - present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual's lifetime.

Health - Pharmacology - 08.09.2020
"These results are crucial for the future corona vaccination strategy"
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.

Life Sciences - Health - 07.09.2020
How to identify new molecular glue degraders
How to identify new molecular glue degraders
Molecular glue degraders are a new class of drugs that work by facilitating an interaction between a disease-causing target protein and a ubiquitin ligase complex, tagging the target protein for degradation.

Pharmacology - Health - 07.09.2020
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale

Pharmacology - Health - 02.09.2020
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo

Pharmacology - Health - 30.08.2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer

Health - Environment - 28.08.2020
Experts collect information on risks of COVID-19 in wastewater
Experts collect information on risks of COVID-19 in wastewater
The review paper "Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic" was co-authored by 34 contributors from around the world. What was Eawag's contribution? Eberhard Morgenroth: For May 2020 I had been invited to participate in the "International Water Summit" at the Ben-Gurion University in Israel.

Pharmacology - Health - 26.08.2020
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.

Health - Life Sciences - 24.08.2020
Breast cancer: New way for tumor cells to escape self-destruction
Breast cancer: New way for tumor cells to escape self-destruction
In the body, so-called programmed cell death prevents cells with irreparable damage from surviving and turning into cancer cells. In the "EMBO Journal", researchers at the University of Basel's Biozentrum, report how a certain protein variant thwarts the self-destruction and thus promotes the growth of breast cancer cells.

Pharmacology - Health - 22.08.2020
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg

Pharmacology - Health - 20.08.2020
FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros

Health - Life Sciences - 18.08.2020
UZH Introduces Five New University Research Priority Programs
The University of Zurich is introducing five new University Research Priority Programs focusing on equal opportunities, human reproduction, rare diseases, digital religions and basic principles of learning.

Pharmacology - Health - 17.08.2020
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o

Pharmacology - Health - 11.08.2020

Life Sciences - Health - 11.08.2020
Wyss Center and Osypka announce collaboration
Wyss Center and Osypka announce collaboration
Pushing the boundaries of implantable neuro-device development Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont,

Pharmacology - Health - 10.08.2020
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
1 2 3 4 5 ... 40 Next »